NeoGenomics, Inc. (NEO) experienced a pre-market plunge of 7.7% on Tuesday, February 18, as the company's fourth-quarter results fell short of analysts' expectations.
In its latest earnings report, NeoGenomics posted a quarterly loss per share of $0.12, missing the consensus estimate of $0.03 earnings per share. The company's revenue for the quarter came in at $172 million, slightly below the FactSet projection of $173.2 million.
Despite the disappointing quarterly performance, NeoGenomics reaffirmed its full-year 2025 guidance, which projects earnings per share of $0.20 and revenue of $733 million. However, investors seemed to focus more on the near-term disappointment, sending the stock tumbling in pre-market trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。